© 2026 Sinochem Nanjing Corporation,
All Right Reserved
|
HS Code |
110535 |
As an accredited 5-Bromo-1,2,3,4-Tetrahydroquinoline factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | |
| Shipping | |
| Storage |
Competitive 5-Bromo-1,2,3,4-Tetrahydroquinoline prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please call us at +8615371019725 or mail to admin@sinochem-nanjing.com.
We will respond to you as soon as possible.
Tel: +8615371019725
Email: admin@sinochem-nanjing.com
Flexible payment, competitive price, premium service - Inquire now!
Chemistry often feels like a world of endless compounds, many with names longer than this paragraph. Among them, 5-Bromo-1,2,3,4-tetrahydroquinoline stands out for how researchers and industry leaders approach challenging syntheses. Looking at this compound takes me back to tough years in the lab, spent hunting for reliable building blocks to tack on or swap out parts of a molecule with minimum fuss. 5-Bromo-1,2,3,4-tetrahydroquinoline always felt like an asset. Anyone running a medicinal chemistry line or piecing together functional materials knows how often you wrestle with finding just the right brominated precursor. Here, there’s no fluff—straightforward quinoline core, one bromo right where you want it, plus reduced aromaticity, which opens up so many synthetic routes.
On paper, it’s C9H10BrN. You get the classic bicyclic quinoline skeleton, hydrogenated on the 1,2,3,4-positions, and a single bromine at the number-five carbon. Tetrahydroquinoline structures have played a part in both life-saving pharmaceuticals and convenience chemicals—anything from antimalarials to dyes. Tagging the five-position with bromine is no accident; this functionalization primes the compound for Suzuki and Buchwald-Hartwig cross-coupling, or further substitution, without clogging up other positions unnecessarily. I remember once working on analogs of a CNS-active drug where only the five position could take the lipophilic handle without killing activity or toxifying the compound. This intermediate fit the bill, letting us move on quickly, rather than spinning our wheels fighting steric hindrance somewhere less accommodating.
Most brominated aromatics promise “reactivity” but bring unnecessary risk or synthetic headache. 5-Bromo-1,2,3,4-tetrahydroquinoline takes the edge off—reactive but not wild, selective enough to avoid trashing your target structure. This matters. It matters when you’re looking at your grant clock, racing to get a hit series out the door, or scaling up a batch for a demanding client who won’t accept inconsistencies. Large-scale production is feasible; the intermediate isn’t one of those “we can only get five grams this year” deal-breakers. As a result, it’s familiar to chemical suppliers and big pharma alike. Teams in lead optimization or chemical biology often lean on this molecule when they need to slip a handle into a rigid scaffold—especially where direct halogenation fails or brings too many side products. The reliability is more than convenience; it’s a chain of trust in synthetic progress.
Choices abound in the catalog—fluoro, chloro, and iodo derivatives crop up in similar projects. I’ve handled 5-chloro-1,2,3,4-tetrahydroquinoline and its kin before. Chlorinated versions stand up well in some nucleophilic substitutions but can play coy in cross-couplings, requiring harsher conditions and giving less yield. Iodo derivatives have their fans for certain couplings but cost more, bring heavier atoms, and sometimes introduce unwanted reactivity—especially under mild conditions. Bromine, especially at the five-position, strikes the right balance: strong leaving ability without dragging a ball and chain through the synthetic plan. Reaction conditions don’t need to reach the extremes often needed for chloro analogs, and the end products end up cleaner.
Physical properties help too. At room temp, this compound handles well, without the volatility or sensitivity of some halogenated aromatics. Storage is stable outside of direct sunlight and humidity—another relief for anyone tired of watching stocks degrade over a long project. In my own bench days, having a stable, easy-to-weigh, and bottle-ready solid kept mistakes lower and reduced the headaches around accurate reaction set-up. NMR and HPLC characterization come straightforward—clean aromatic shifts, no overlapping with odd solvents or minor impurities. The reduced ring, compared to fully aromatic quinolines, tunes its reactivity just right for stepwise transformations, while its solid nature makes it easier to purify and isolate.
Focus shifts naturally to medicinal chemistry. Oncology teams, CNS research, anti-infectives: all continue to invest in the quinoline core, and the partially saturated scaffold can give better solubility and escape the metabolic liabilities of fully aromatic systems. Brominated intermediates like this mean rapid diversification—in the space of a single day, I’ve seen libraries of analogs spun out through cross-coupling, providing a way to explore structure-activity relationships systematically. This isn’t a molecule that hogs the limelight, but it enables breakthrough results elsewhere. For teams who need structure modifications, 5-Bromo-1,2,3,4-tetrahydroquinoline often beats more exotic, harder-to-source precursors.
No compound is perfect. Handling high-concentration solutions calls for basic safety—brominated organics still rank as skin and environmental irritants. Waste management also matters. Responsible chemists capture and treat brominated residues—nobody wants halogens lingering in groundwater. Scale-up also exposes issues with solubility in some nonpolar solvents, so larger productions need careful solvent selection. Still, compared to analogous halides, practical headaches with 5-Bromo-1,2,3,4-tetrahydroquinoline are manageable.
Resources in the lab aren’t infinite. Using a versatile, reliable building block makes planning easier and costs, literally, less in terms of failed reactions. There is something satisfying about skipping synthetic gymnastics and moving from compound to analog, testing a hypothesis in a timely manner. Having run optimization projects myself, bottlenecks almost always came down to finicky intermediates or trouble scaling up early-stage hits. With 5-bromo on board, developing new analogs or derivatives became straightforward. Whether for amide coupling, arylation, or even reductive amination, predictable reactivity keeps projects moving.
Drug development relies on more than good chemistry. Regulatory acceptance also depends on the reliability and safety record of intermediates. 5-Bromo-1,2,3,4-tetrahydroquinoline appears regularly in preclinical research and meets industry-standard purity and documentation requirements when sourced from reputable suppliers. This confidence means that legal or compliance teams have clear precedents and reference materials, helping projects move past due diligence with less uncertainty. Don’t underestimate the relief this gives when justifying a synthesis plan to higher-ups or external partners.
Sustainability sits front and center in chemical development. Halogenated intermediates require careful review, both for manufacturing and for their downstream impacts. Experience has shown that controlled synthesis, coupled with responsible waste management, mitigates risks from brominated aromatics. Many suppliers have worked toward greener processes and safer transport, focusing on minimizing leaks, exposure, or accidental contamination. In my experience, teams that plan recycling or neutralization up front face far fewer headaches than those treating waste after the fact. End users—whether academic or industry—bear responsibilities to minimize environmental release.
Not all quinoline derivatives bring equal value. Synthesis of 5-Bromo-1,2,3,4-tetrahydroquinoline typically runs through well-established sequences—starting with quinoline or tetrahydroquinoline, selective bromination gives the product without complex protection-deprotection steps. Compared to more exotic quinoline halides, this keeps costs in check. Feedback from purchasing departments across several institutions has confirmed consistent supply lines and pricing without seasonal interruptions, even when demand from pharma spikes. These real-world logistics affect timelines and budget more than many realize until crunch time approaches.
Interest in functionalized tetrahydroquinolines continues to grow as new applications emerge—imaging agents, ligands for protein target discovery, and precursors for functional materials. Customization, using a reliable bromo handle, allows scientists to tack on fluorescent tags, extended linkers, or complex substituents without breaking the core structure. In my own work tracing protein interactions, starting from a clean, bromo-activated scaffold gave cleaner results and better recovery of key metabolites. Similar trends appear in catalysis, where the partially saturated backbone resists degradation and enables more diverse ligand design.
Scaling discoveries to production size always brings a new set of challenges—solubility, isolation, purity, and batch consistency. Reliable precursors like 5-Bromo-1,2,3,4-tetrahydroquinoline smooth this transition, offering solubility profiles and reactivity levels consistent enough for standardized protocols. I’ve seen high-throughput labs cut cycle times dramatically by settling on this intermediate early rather than cycling through dozens of less predictable candidates. The capacity to handle kilogram quantities while retaining purity and handling stability means fewer surprises as one moves from flask to reactor scale.
Every chemist knows you can’t take health and safety for granted, especially with halogenated intermediates. 5-Bromo-1,2,3,4-tetrahydroquinoline asks for routine precautions: gloves, eyewear, fume hoods. That said, day-to-day handling brings fewer acute hazards than some more volatile or reactive halides—compare it to, say, iodobenzenes or alkyl chlorides with their biting odors and acute toxicities, and you appreciate the manageable risk profile. As always, keeping MSDS documents close, following good laboratory practice, and storing the chemical properly means any lab can use it safely day after day.
For many junior chemists, running reactions with a forgiving and reliable reagent builds experience and momentum. My first direct arylation that succeeded—after frustrating failures—used 5-Bromo-1,2,3,4-tetrahydroquinoline. Watching the NMR reveal clean coupling without chasing down byproducts felt like progress that any early-career researcher chases. These early wins do more than move research forward; they keep morale up and motivate deeper dives on structure-function relationships.
Group projects often hinge on available, reliable compounds that colleagues can order and receive quickly. Discussions across departments—from medicinal chemists to process engineers—grow easier when the basic building blocks are familiar and the literature references go back decades. With 5-bromo tetrahydroquinolines, collaborations move faster as nobody spends precious time re-justifying their choice of starting material. Reliability and literature precedent anchor the project, letting colleagues focus their debate on new ideas and hypotheses.
Scientific credibility rests on the ability to reproduce experiments and scale up protocols. Because 5-Bromo-1,2,3,4-tetrahydroquinoline boasts clear, straightforward syntheses and robust handling guidelines, projects that use it generate fewer batch-to-batch differences and reduce risk of irreproducibility. Consistent spectral purity and expected reactivity build confidence across academic papers, patent submissions, and internal development reports. In publication and patenting, references that use common intermediates boost the credibility and acceptance of new variants—this intermediate frequently appears in the literature for precisely those reasons.
No amount of planning avoids every hiccup. Solubility issues, unexpected scale-up effects, or equipment failures can turn routine syntheses into learning experiences. My team once hit a snag during scale-up, as viscosity increased faster than expected. Tweaking solvent composition and dropwise addition rescued the batch—likely a familiar episode for anyone who’s ever run a reaction at 100 times normal scale. The transparency of 5-Bromo-1,2,3,4-tetrahydroquinoline’s behavior under standard lab analysis (TLC, HPLC, etc.) lets chemists troubleshoot quickly and get back on track. Its predictable response to changes in base, temperature, or solvent simplifies method development.
In fields as diverse as pharmaceuticals, pigments, and agrochemicals, building blocks like 5-Bromo-1,2,3,4-tetrahydroquinoline mean more than one lucky reaction. They open doors to making molecules with precise activity, improved safety, and tunable properties—qualities central to both public health and commercial success. More flexible chemistry leads to safer, more sustainable consumer products. The progress we’ve witnessed in drug and material development owes much to iterative work using small-molecule intermediates that don’t hog attention but do sustain progress.
Looking for better yields? Careful choice of catalysts and bases, particularly for Suzuki coupling, can make a night-and-day difference, and I’ve often reached for palladium-based systems with strong phosphine ligands for the cleanest reactions. Want purer product? Don’t overlook charcoal filtration or flash chromatography on neutral alumina—both work well for this compound. For scale-up, temperature ramp profiles and overhead stirring prevent the solid from clumping or sticking. Making use of automated or semi-automated purification reduces batch variability, especially for teams preparing libraries or routine supplies.
Year after year, the best chemical catalogs restock 5-bromo-1,2,3,4-tetrahydroquinoline in multiple batch sizes. Rapid shipping and international warehouse support keep labs running—even when supply chains snarl elsewhere. From my own experience, nothing brings a synthetic campaign to a halt faster than a back-ordered or discontinued intermediate. Regular supplier vetting, and building relationships with vendors who maintain batch records and update certificate of analysis information, prevent almost all procurement problems.
Emerging technologies—machine-assisted reaction design and automated synthetic optimization—are beginning to demand predictable, well-documented intermediates more than ever. As computational chemistry generates new analogs, and green chemistry standards tighten, I expect 5-Bromo-1,2,3,4-tetrahydroquinoline to see even broader deployment. Its combination of familiar reactivity, stable handling, and established synthetic flexibility fit new trends in both discovery and process development. Specialized applications in materials science and diagnostics are likely to follow, with researchers building on the confidence and reproducibility that have defined this compound’s legacy so far.
Every chemist has a handful of prefatory molecules that define productive periods in their research. 5-Bromo-1,2,3,4-tetrahydroquinoline sits on that short list for many. Whether you’re a veteran process chemist or a new graduate building your first compound library for screening, the value of a robust, flexible, easy-to-handle intermediate can't be overstated. This compound’s practical benefits—predictable behavior, widespread availability, and broad utility—reflect what makes chemistry more transparent, more reliable, and ultimately more successful. The continued use and refinement of intermediates like this one keeps laboratories innovating and industry responding to new challenges with confidence.
The utility and widespread adoption of 5-Bromo-1,2,3,4-tetrahydroquinoline appears throughout published papers and chemical supplier catalogs, especially in the fields of medicinal and organic chemistry. Leading journals regularly discuss the use of halogenated quinolines in synthetic campaigns, and regulatory filings often mention similar compounds as key intermediates in new drug entities. As demand increases for specialty molecules that meet both regulatory standards and synthetic needs, intermediates with a substantial literature base and practical handling profile are likely to remain in high demand across chemical enterprise.
